5-{8-[(3,4′-Difluoro[1,1′-biphenyl]-4-yl)methoxy]-2-methylimidazo[1,2-a]pyridin-3-yl}-N-methylpyridine-2-carboxamide (1o) exhibited high in vitro potency and brain exposure, was able to cause a significant reduction in brain Aβ42 levels, and had no inhibitory effect on cytochrome p450 enzymes. In addition, compound 1o exhibited excellent anti-cognitive deficits in AD model mice.